Targeting the IL-33/ST2 axis has shown potential for controlling excessive lung inflammation [27]; several phase 2 trials are investigating anti-ST2 and anti-IL-33 antibodies as therapies for other inflammatory diseases, such as COPD (ClinicalTrials.gov: NCT03546907 and NCT03615040) and asthma (ClinicalTrials.gov: NCT03207243) [28]. This evidence concerns the gene IL33 and asthma.